Dyadic International (NASDAQ:DYAI) Issues Quarterly Earnings Results

Dyadic International (NASDAQ:DYAI) posted its quarterly earnings results on Wednesday. The biotechnology company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01), FiscalAI reports. The business had revenue of $1.11 million during the quarter, compared to analysts’ expectations of $0.90 million. Dyadic International had a negative net margin of 192.40% and a negative return on equity of 661.11%.

Here are the key takeaways from Dyadic International’s conference call:

• Dyadic said it is transitioning from a platform company to a more commercial biotech, with products now launched, shipped, sampled, and beginning to generate revenue through direct sales, OEM distribution, milestone payments, and partnerships.
• Q1 2026 revenue rose 182% year over year to about $1.1 million, driven largely by higher R&D and grants-related activity, while the net loss improved modestly to about $1.95 million.
• The company highlighted multiple commercialization wins, including Proliant’s launch of AlbuFree DX, Enzymes’ commercial launch of recombinant bovine chymosin, and first commercial shipments of DNase I and transferrin through its IBT Bioservices distribution agreement.
• Management said customer interest is increasing across life sciences, food and nutrition, and industrial markets, including initial purchase orders in cultivated meat and expanded sampling in Asia-Pacific and Europe through partners like Intralink and FermBox Bio.
• Dyadic ended the quarter with about $6.6 million in cash, restricted cash, and investment-grade securities, and management reiterated that existing resources should fund operations into Q2 2027 if cash burn stays near recent levels.

Dyadic International Trading Up 5.8%

Shares of NASDAQ:DYAI traded up $0.04 during trading on Friday, reaching $0.73. 43,010 shares of the stock were exchanged, compared to its average volume of 65,721. The company has a debt-to-equity ratio of 4.08, a quick ratio of 2.68 and a current ratio of 2.68. Dyadic International has a 12-month low of $0.65 and a 12-month high of $1.35. The firm has a market cap of $26.60 million, a price-to-earnings ratio of -3.17 and a beta of 1.18. The firm’s 50-day moving average price is $0.81 and its 200 day moving average price is $0.88.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Dyadic International in a report on Friday, March 27th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $3.00.

Hedge Funds Weigh In On Dyadic International

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE raised its position in shares of Dyadic International by 16,146.7% in the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 26,965 shares in the last quarter. Landscape Capital Management L.L.C. acquired a new position in shares of Dyadic International in the 3rd quarter valued at approximately $190,000. Finally, Geode Capital Management LLC raised its position in shares of Dyadic International by 13.7% in the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after purchasing an additional 36,266 shares in the last quarter. 27.95% of the stock is owned by institutional investors and hedge funds.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.